Eye injection could replace corneal transplants for swelling

NCT ID NCT06041256

Completed Disease control Sponsor: Aurion Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This clinical trial tested a new treatment called AURN001 for people with corneal edema, a condition where the cornea swells due to damaged cells. The treatment is a single injection into the eye that combines donor corneal cells with a drug to help them work. The study involved 97 participants and compared different doses to see if it safely improves vision. The goal is to offer an alternative to corneal transplant surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AURN001 (a combination of corneal endothelial cells and Y27632 drug)
What this could lead to: If successful, this could lead to a non-surgical injection treatment for corneal edema, potentially replacing or delaying the need for corneal transplant surgery.
What could go wrong: This is an early-phase trial (phase 1/2) with only 97 participants, so results may not apply to everyone. The treatment is still experimental, and long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal edema secondary corneal edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORNEAL EDEMA CORNEAL ENDOTHELIAL DYSFUNCTION

Contacts and locations

Show contact details

Locations

Aurion Biotech site

Little Rock, Arkansas, 72205, United States
Aurion Biotech site

Los Angeles, California, 90067, United States
Aurion Biotech site

San Francisco, California, 94158, United States
Aurion Biotech site

Atlanta, Georgia, 30339, United States
Aurion Biotech site

Indianapolis, Indiana, 46260, United States
Aurion Biotech site

Wichita, Kansas, 67206, United States
Aurion Biotech site

Minnetonka, Minnesota, 55305, United States
Aurion Biotech site

Garden City, New York, 11576, United States
Aurion Biotech site

Winston-Salem, North Carolina, 27157, United States
Aurion Biotech site

Cincinnati, Ohio, 45242, United States
Aurion Biotech site

Oklahoma City, Oklahoma, 73104, United States
Aurion Biotech site

Bala-Cynwyd, Pennsylvania, 19004, United States
Aurion Biotech site

Sioux Falls, South Dakota, 57108, United States
Aurion Biotech site

Houston, Texas, 77027, United States
Aurion Biotech site

Houston, Texas, 77055, United States
Aurion Biotech site

Norfolk, Virginia, 23502, United States
Aurion Biotech site

Seattle, Washington, 98125, United States
Aurion Biotech site

Vancouver, British Columbia, V5Z 1K1 CAN, Canada
Aurion Biotech site

Oakville, Ontario, L6H 0J8 CAN, Canada
Aurion Biotech site

Toronto, Ontario, M5T 3A9 CAN, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.